Examkin

Question

Difficulty: MediumGynecologic Oncology

An oncologist refers a 58-year-old patient to the gynecology clinic after she reports a recent episode of dark red vaginal spotting. She underwent breast-conserving surgery and radiation for early-stage hormone receptor-positive breast cancer three years ago. Since her surgery, she has been maintained on adjuvant tamoxifen therapy. The patient's last menstrual period occurred naturally at age 52. She denies pelvic pain, dysuria, or systemic symptoms. Her body mass index is 26 kg/m226 \text{ kg/m}^2. Speculum examination demonstrates pale, thinned vaginal walls with a small amount of blood in the vaginal vault. The cervix appears grossly normal without lesions. Which of the following is the most appropriate next step in management?

  1. A
    Transvaginal ultrasonography
  2. B
    Discontinuation of tamoxifen therapy
  3. Endometrial biopsyAnswer
  4. D
    Cervical cytology and HPV cotesting
  5. E
    Reassurance and clinical observation

Answer

Endometrial biopsy
The correct answer is endometrial biopsy. Any postmenopausal bleeding must be thoroughly investigated to rule out endometrial carcinoma. While transvaginal ultrasonography (TVUS) is often an appropriate initial triage step for the general postmenopausal population, it is contraindicated as a primary tool for patients currently taking tamoxifen. Tamoxifen exerts an estrogenic effect on the endometrium and frequently causes subepithelial stromal hypertrophy. This creates a falsely thickened and cystic appearance on ultrasound, rendering the imaging modality highly unreliable. Therefore, patients on tamoxifen who present with postmenopausal bleeding require direct tissue sampling via endometrial biopsy as the initial diagnostic step.

Step-by-Step Solution

1
Analyze the patient's symptoms and relevant medical history.
The patient is a postmenopausal woman presenting with new-onset vaginal bleeding while taking tamoxifen for breast cancer.
Identifying the combination of postmenopausal bleeding and tamoxifen use dictates a specific diagnostic pathway that differs from the general postmenopausal population.
2
Determine the diagnostic requirements for this specific clinical presentation.
Tamoxifen is a selective estrogen receptor modulator that has an estrogenic, proliferative effect on the endometrium and causes subepithelial stromal hypertrophy.
Because of these pharmacologic effects, imaging modalities like ultrasound will almost always show a falsely thickened, cystic endometrium, making them unreliable.
3
Select the definitive next step in management.
Endometrial biopsy is indicated.
An endometrial biopsy directly samples the tissue, completely bypassing the sonographic artifacts caused by tamoxifen, to definitively rule out endometrial hyperplasia or carcinoma.

Key Concept

In patients taking tamoxifen, postmenopausal bleeding must be initially evaluated with an endometrial biopsy rather than transvaginal ultrasonography due to tamoxifen-induced subepithelial stromal hypertrophy causing false-positive thickened stripes on imaging.
Rate this question

Topics

Gynecologic Oncology

More questions from this topic